Healthcare Economics Data

Evidence / Healthcare Economics

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial

PUBLICATION: European Journal of Cancer AUTHORS: Valesca P. Retel, Danalyn Byng, Sabine C. Linn, Katarzyna Jozwiak, Hendrik Koffijberg, Emiel J. Rutgers, Fatima Cardoso, Martine J. Piccart, Coralie Poncet, Laura J. van ’t Veer, Wim H. van Harten. Abstract: The clinical utility of the 70-gene signature (MammaPrint®) to guide chemotherapy Read More

Genomic Profile of Breast Cancer: Cost-Effectiveness Analysis from the Spanish National Healthcare System Perspective

PUBLICATION: Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):889-99. doi: 10.1586/14737167.2014.957185. Epub 2014 Sep 12. AUTHORS: Seguí M.Á., Crespo C., Cortés J., Lluch A., Brosa M., Becerra V., Chiavenna S.M., Gracia A. SUMMARY: A 70-gene signature showed a life expectancy of 23.55 years at lifetime. Life expectancy was lower for 21-gene Read More

Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses

PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):621-37. doi: 10.1007/s10549-013-2559-1. Epub 2013 May 31. AUTHORS: Rouzier R., Pronzato P., Chéreau E., Carlson J., Hunt B., Valentine W.J. SUMMARY: Systematic Review: The review identified 29 publications that reported evaluations of two assays: Oncotype DX(®) and MammaPrint. Studies of both tests provided evidence Read More

Economic Evaluation of the 70-gene Prognosis-Signature (MammaPrint®) in Hormone Receptor-Positive, Lymph Node-Negative, Human Epidermal Growth Factor Receptor Type 2-Negative Early Stage Breast Cancer in Japan

PUBLICATION: Breast Cancer Res Treat. 2012 Jun;133(2):759-68. doi: 10.1007/s10549-012-1979-7. AUTHORS: Kondo M., Hoshi S.L., Ishiguro H., Toi M. SUMMARY: The introduction of the assay into Japanese practice of ER+, LN−, HER2− ESBC treatment by including it to Japan’s social health insurance benefit package has a reasonable chance to be judged Read More